Transcatheter Aortic Valve Implantation Market by Procedure - Global Opportunity Analysis and Industry Forecast, 2018-2025

  • ID: 4603645
  • Report
  • Region: Global
  • 143 pages
  • Allied Analytics LLP
1 of 4
The transcatheter aortic valve implantation (TAVI) market revenue was valued at $2,761 million in 2017 and is expected to reach $8,138 million by 2025, growing at a CAGR of 13.8% from 2018 to 2025. The volume market was valued at 107,011 units in 2017 and is expected to reach 337,778 units by 2025, growing at a CAGR of 14.8% from 2018 to 2025.

Transcatheter aortic valve implantation (TAVI), also called as transcatheter aortic valve replacement (TAVR), is a minimally invasive surgical procedure, which is performed to treat high-risk patients suffering from aortic stenosis. These high-risk patients refer to the patient population who cannot undergo surgical aortic valve replacement (SAVR) procedure. Older population (above 75 years of age) falls under the high-risk category, as the open-heart procedure is too risky for them. TAVR involves implantation of transcatheter aortic valves to regenerate the blood circulation ability of the aortic valve. The need of transcatheter aortic valve implantation is on the rise due to the increase in prevalence of aortic stenosis.

TAVI experiences market growth due to rise in geriatric population. Furthermore, advancements in the transcatheter aortic valves and increase in adoption rate of TAVI devices drive the market. However, stringent government regulations for approval of transcatheter aortic valves, which are class III medical devices and high cost associated with TAVI hamper the market growth. Conversely, use of TAVI systems for new indications, rise in healthcare expenditure in emerging economies, and increase in the interest of key players in the TAVI market are projected to provide several growth opportunities for the market throughout the forecast period.

The report segments the TAVI market based on procedure and region. According to procedure, it is classified into transfemoral implantation, transapical implantation, and transaortic implantation. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, Switzerland, UK, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Brazil, Israel, South Africa, Saudi Arabia, and Rest of LAMEA).

KEY BENEFITS

This report provides an extensive analysis of the current and emerging market trends, and dynamics in the global TAVI market.
An in-depth analysis is conducted by constructing market estimations for the key segments between 2017 and 2025.
This report entails the detailed quantitative analysis of the current trends and future estimations through 2017–2025, which assists to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the growth of the TAVI market is provided.
An in-depth analysis of the current research and clinical developments within the TAVI market is provided.
Key players are profiled, and their strategies are analyzed thoroughly, which interprets the competitive outlook of the market.

KEY MARKET SEGMENTS

By Procedure

Transfemoral Implantation
Transapical Implantation
Transaortic Implantation

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
Italy
Switzerland
UK
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
LAMEA
Brazil
Israel
South Africa
Saudi Arabia
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Abbott Laboratories
Boston Scientific Corporation (Symetis SA)
Bracco S.p.A. (HLT, Inc.)
Edwards Lifesciences Corporation
JenaValve Technology, Inc.
JC Medical, Inc.
Medtronic plc
Meril Life Sciences Pvt. Ltd.
NVT AG
Venus Medtech, Inc.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. KEY PLAYERS
1.5. RESEARCH METHODOLOGY
1.5.1. Secondary research
1.5.2. Primary research
1.5.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3: MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of new entrants
3.3.4. Intensity of rivalry
3.3.5. Threat of substitutes
3.4. MARKET SHARE ANALYSIS, 2017
3.5. GOVERNMENT REGULATIONS
3.5.1. U.S. FDA
3.5.2. Europe CE Mark
3.5.3. Ministry of Health, Labour and Welfare (MHLW)
3.6. CLINICAL TRIALS
3.7. MARKET DYNAMICS
3.7.1. Drivers
3.7.1.1. Rise in prevalence of aortic stenosis coupled with increase in geriatric population
3.7.1.2. Increase in adoption rate for transcatheter aortic valve implantation procedure
3.7.1.3. Increase in clinical evidence of safety and efficacy and new device approvals
3.7.1.4. Increase in number of TAVR Centers
3.7.2. Restraints
3.7.2.1. High cost of the device and unfavorable reimbursement policies
3.7.2.2. Stringent regulatory approval process
3.7.3. Opportunities
3.7.3.1. Use of TAVI systems for new indications
3.7.3.2. Rise in healthcare expenditure of developing countries
3.7.3.3. Increase in interest of local to global players in the TAVI market
3.7.4. Impact Analyses

CHAPTER 4: TRANSCATHETER AORTIC VALVE IMPLANTATION MARKET, BY PROCEDURE
4.1. OVERVIEW
4.1.1. Key market trends, growth factors, and opportunities
4.1.2. Market size and forecast
4.1.3. Market volume and forecast
4.2. TRANSFEMORAL (TF) IMPLANTATION
4.2.1. Market size and forecast
4.2.2. Market volume and forecast
4.3. TRANSAPICAL (TA) IMPLANTATION
4.3.1. Market size and forecast
4.3.2. Market volume and forecast
4.4. TRANSAORTIC IMPLANTATION
4.4.1. Market size and forecast
4.4.2. Market volume and forecast

CHAPTER 5: TRANSCATHETER AORTIC VALVE IMPLANTATION MARKET, BY REGION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.1.2. Market volume and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast, by country
5.2.3. Market volume and forecast, by country
5.2.3.1. U.S.
5.2.3.2. Canada
5.2.3.3. Mexico
5.2.4. Market size and forecast, by procedure
5.2.5. Market volume and forecast, by procedure
5.3. EUROPE
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast, by country
5.3.3. Market volume and forecast, by country
5.3.3.1. Germany
5.3.3.2. France
5.3.3.3. Italy
5.3.3.4. Switzerland
5.3.3.5. UK
5.3.3.6. Rest of Europe
5.3.4. Market size and forecast, by procedure
5.3.5. Market volume and forecast, by procedure
5.4. ASIA-PACIFIC
5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast, by country
5.4.3. Market volume and forecast, by country
5.4.3.1. Japan
5.4.3.2. China
5.4.3.3. India
5.4.3.4. Rest of Asia-Pacific
5.4.4. Market size and forecast, by procedure
5.4.5. Market volume and forecast, by procedure
5.5. LAMEA
5.5.1. Key market trends, growth factors, and opportunities
5.5.2. Market size and forecast, by country
5.5.3. Market volume and forecast, by country
5.5.3.1. Brazil
5.5.3.2. South Africa
5.5.3.3. Israel
5.5.3.4. Saudi Arabia
5.5.3.5. Rest of LAMEA
5.5.4. Market size and forecast, by procedure
5.5.5. Market volume and forecast, by procedure

CHAPTER 6: COMPANY PROFILES
6.1. ABBOTT LABORATORIES (ST. JUDE MEDICAL, INC.)
6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance
6.1.6. Key strategic moves and developments
6.2. BOSTON SCIENTIFIC CORPORATION (SYMETIS SA)
6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Business performance
6.2.6. Key strategic moves and developments
6.3. BRACCO S.P.A. (HLT, INC.)
6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance
6.4. EDWARDS LIFESCIENCES CORPORATION
6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance
6.4.6. Key strategic moves and developments
6.5. JENAVALVE TECHNOLOGY, INC.
6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Product portfolio
6.6. JC MEDICAL, INC.
6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Product portfolio
6.6.4. Key strategic moves and developments
6.7. MEDTRONIC PLC.
6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance
6.7.6. Key strategic moves and developments
6.8. MERIL LIFE SCIENCES PVT. LTD.
6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.9. NVT AG
6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Product portfolio
6.10. VENUS MEDTECH, INC.
6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Product portfolio
6.10.4. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report, titled, Transcatheter Aortic Valve Implantation (TAVI) Market by Procedure: Global Opportunity Analysis and Industry Forecast, 2018-2025, the market revenue was valued at $2,761 million in 2017 and is expected to reach $8,138 million by 2025, growing at a CAGR of 13.8% from 2018 to 2025. The volume market was valued at 107,011 units in 2017 and is expected to reach 337,778 units by 2025, growing at a CAGR of 14.8% from 2018 to 2025.

Transcatheter aortic valve implantation (TAVI), also called as transcatheter aortic valve replacement (TAVR), is a minimally invasive surgical procedure, which is performed to treat high-risk patients suffering from aortic stenosis. These high-risk patients refer to the patient population that are inoperable and cannot undergo surgical aortic valve replacement (SAVR) procedure. Older population (above 75 years of age) falls under the high-risk category, as the open-heart procedure is too risky for them. TAVR involves implantation of transcatheter aortic valves to regenerate the blood circulation ability of the aortic valve. The need of transcatheter aortic valve implantation is on the rise due to the increase in prevalence of aortic stenosis.

The TAVI market is in its growth phase, and is mainly driven by rise in prevalence of aortic stenosis and increase in geriatric population. In addition, increase in adoption rate of transcatheter aortic implantation along with new device approvals and improvement of healthcare infrastructure in developing countries are other factors that fuel the market growth. However, high cost of transcatheter aortic valve and its implantation procedures, along with lack of reimbursement and stringent approvals for these devices, hamper the growth of the TAVI market.

The report segments the TAVI market based on the approach used for implantation. Mainly, three types of approaches are used to implant the transcatheter aortic valve in patients-transfemoral, transapical, and transaortic implantation. Transfemoral implantation was the highest revenue-generating segment in the global market (in terms of value and volume) in 2017, as it does not require a chest incision. Furthermore, transaortic segment is projected to grow at the highest CAGR of 19.1% (in terms of value) and 20.1% (in terms of volume) by 2025, due to positive outcomes of several clinical trials.

Key Findings of the Transcatheter Aortic Valve Implantation (TAVI) Market:

In 2017, transfemoral implantation generated the highest revenue, and is projected to grow at a CAGR of 13.2% (in terms of value) during the forecast period.
Both in terms of value and volume, the Europe TAVI market is expected to maintain its leading position during the forecast period.
Asia-Pacific is expected to be the fastest growing region, and is expected to grow with a CAGR of 18.6% (in terms of value) from 2018 to 2025.
Germany was the leading country whereas the UK is projected to be the fastest growing country in the Europe TAVI market.
India is the fastest growing country in the Asia-Pacific TAVI market and is expected to grow at a CAGR of 29.8% (in terms of revenue) from 2018 to 2025.

Europe accounted for a major share in the global TAVI market (in terms of value and volume) in 2017, and is expected to maintain this trend. This is attributed to the rise in prevalence of severe aortic stenosis cases coupled with the increase in population of inoperable patients, and high adoption rate of advanced transcatheter aortic valves. However, Asia-Pacific is estimated to grow at a high CAGR (in terms of value and volume) throughout the Analysis period, owing to the presence of ample growth opportunities in terms of unmet medical needs for the treatment of aortic stenosis and increase in awareness about TAVI procedures among physicians.

Key players have adopted product approval as their key strategy to enhance their product offerings by expanding the usage of transcatheter aortic valves for new indications, such as intermediate risk aortic stenosis patients. The key players profiled in this report include Abbott Laboratories, Boston Scientific Corporation (Symetis SA), Bracco S.p.A. (HLT, Inc.), Edwards Lifesciences Corporation, JeValve Technology, Inc., JC Medical, Inc., Medtronic plc, Meril Life Sciences Pvt. Ltd., NVT AG, and Venus Medtech, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll